Department of Epidemiology

News

Blood Biomarkers for Use in Alzheimer Disease—Moving From “If” to “How?”

Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2

See the full article on JAMA

Share to...

you may also be interested in …

GSA 2025 Comes to a Close

GSA 2025 Comes to a Close

,

Members of eBrain (Dr. Meredith Phillips, Erica Fan, Dr. Andrea Rosso and Greta Cheng) presented in their session "Social Determinants of Cognitive and Brain Aging: novel approaches and new findings". Congratulations to all participants of the GSA 2025 Scientific...

Ending Summer with our PNA Social!

Ending Summer with our PNA Social!

,

PNA said goodbye to Summer 25', sharing what was accomplished over the last few months. Along with great conversation and food, our team congratulated and thanked predoctoral trainee Shruthi Venkatesh for her time on our Training Grant!

The Hidden Link between Racism and Alzheimer’s Risk

The Hidden Link between Racism and Alzheimer’s Risk

,

Dr. Andrea Rosso and Dr. Beth Shaaban shared their expertise with Scientific American on how Racial Discrimination can be linked to higher risks of an Alzheimer's diagnosis. The article, published by journalist Jyoti Madhusoodanan, can be found in How Racial...